

# Leslie Z Benet, Fcp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7026649/publications.pdf>

Version: 2024-02-01

209  
papers

21,707  
citations

16437

64  
h-index

9579

142  
g-index

212  
all docs

212  
docs citations

212  
times ranked

13240  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 215-236.   | 21.5 | 2,886     |
| 2  | Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. <i>Pharmaceutical Research</i> , 2005, 22, 11-23. | 1.7  | 1,222     |
| 3  | Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. <i>Molecular Carcinogenesis</i> , 1995, 13, 129-134.  | 1.3  | 780       |
| 4  | Noncompartmental Determination of the Steady-State Volume of Distribution. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 1071-1074.   | 1.6  | 724       |
| 5  | Changes in plasma protein binding have little clinical relevance. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 115-121.  | 2.3  | 680       |
| 6  | Clearance concepts in pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1973, 1, 123-136.   | 0.6  | 674       |
| 7  | Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 248-260.   | 2.3  | 654       |
| 8  | BDDCS Applied to Over 900 Drugs. <i>AAPS Journal</i> , 2011, 13, 519-547.   | 2.2  | 532       |
| 9  | BDDCS, the Rule of 5 and drugability. <i>Advanced Drug Delivery Reviews</i> , 2016, 101, 89-98.   | 6.6  | 475       |
| 10 | The Gut as a Barrier to Drug Absorption. <i>Clinical Pharmacokinetics</i> , 2001, 40, 159-168.  | 1.6  | 468       |
| 11 | Gender Effects in Pharmacokinetics and Pharmacodynamics. <i>Drugs</i> , 1995, 50, 222-239.  | 4.9  | 438       |
| 12 | Acyl Glucuronides Revisited: Is the Glucuronidation Process a Toxication as Well as a Detoxification Mechanism?. <i>Drug Metabolism Reviews</i> , 1992, 24, 5-47.   | 1.5  | 393       |
| 13 | Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 717-733.   | 6.6  | 379       |
| 14 | The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs. <i>Pharmaceutical Research</i> , 2009, 26, 2039-2054.  | 1.7  | 375       |
| 15 | Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 492-497.   | 2.3  | 340       |
| 16 | Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 453-457.                        | 2.3  | 327       |
| 17 | Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 194-204.   | 2.3  | 297       |
| 18 | Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 1036-1045.  | 1.3  | 287       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. <i>Journal of Controlled Release</i> , 1999, 62, 25-31.   | 4.8  | 279       |
| 20 | Intestinal drug transporters: An overview. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1340-1356.  | 6.6  | 265       |
| 21 | The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 15-19.  | 2.3  | 263       |
| 22 | Active secretion and enterocytic drug metabolism barriers to drug absorption IPII of original article: S0169-409X(96)003304. The article was originally published in <i>Advanced Drug Delivery Reviews</i> 20 (1996) 99-112.1. <i>Advanced Drug Delivery Reviews</i> , 2001, 46, 89-102. | 6.6  | 257       |
| 23 | Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 41-49.   | 2.3  | 254       |
| 24 | Effects of renal failure on drug transport and metabolism. , 2006, 109, 1-11.  |      | 248       |
| 25 | The Role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug) Tj ETQq1 1 0.784314 rgBT /Overlock 10<br>34-42.   | 1.6  | 242       |
| 26 | Mouse liver repopulation with hepatocytes generated from human fibroblasts. <i>Nature</i> , 2014, 508, 93-97.  | 13.7 | 232       |
| 27 | The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 24-31.  | 2.3  | 187       |
| 28 | General Treatment of Linear Mammillary Models with Elimination from any Compartment as Used in Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1972, 61, 536-541.  | 1.6  | 182       |
| 29 | The Drug Transporterâ”™Metabolism Alliance: Uncovering and Defining the Interplay. <i>Molecular Pharmaceutics</i> , 2009, 6, 1631-1643.  | 2.3  | 176       |
| 30 | Grapefruit juice activates P-glycoprotein-mediated drug transport. <i>Pharmaceutical Research</i> , 1999, 16, 478-485.   | 1.7  | 173       |
| 31 | Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery. <i>Journal of Controlled Release</i> , 1996, 39, 139-143.  | 4.8  | 166       |
| 32 | In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 306-314.  | 1.3  | 151       |
| 33 | Active secretion and enterocytic drug metabolism barriers to drug absorption. <i>Advanced Drug Delivery Reviews</i> , 1996, 20, 99-112.  | 6.6  | 149       |
| 34 | Relationship between the pharmacokinetics and pharmacodynamics of procainamide. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 278-289.   | 2.3  | 148       |
| 35 | Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drugâ”™Drug Interaction Potential for Molecular Targeted Agents in Clinical Development. <i>Molecular Pharmaceutics</i> , 2013, 10, 4055-4062.  | 2.3  | 143       |
| 36 | Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 762-771.   | 1.3  | 136       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | P-glycoprotein (P-gp/MDR1)-Mediated Efflux of Sex-Steroid Hormones and Modulation of P-gp Expression In Vitro. <i>Pharmaceutical Research</i> , 2004, 21, 1284-1293.  | 1.7 | 129       |
| 38 | The Use of BDDCS in Classifying the Permeability of Marketed Drugs. <i>Pharmaceutical Research</i> , 2008, 25, 483-488.   | 1.7 | 124       |
| 39 | The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 297-303.   | 2.3 | 119       |
| 40 | Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 78-85. | 2.3 | 119       |
| 41 | EFFECTS OF UREMIC TOXINS ON HEPATIC UPTAKE AND METABOLISM OF ERYTHROMYCIN. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1239-1246.  | 1.7 | 117       |
| 42 | Effects of Drug Transporters on Volume of Distribution. <i>AAPS Journal</i> , 2009, 11, 250-261.  | 2.2 | 116       |
| 43 | Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 643-653.  | 1.0 | 115       |
| 44 | Drug Discovery and Regulatory Considerations for Improving In Silico and In Vitro Predictions that Use Caco-2 as a Surrogate for Human Intestinal Permeability Measurements. <i>AAPS Journal</i> , 2013, 15, 483-497.   | 2.2 | 113       |
| 45 | Ex Situ Inhibition of Hepatic Uptake and Efflux Significantly Changes Metabolism: Hepatic Enzyme-Transporter Interplay. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 1040-1045.  | 1.3 | 104       |
| 46 | PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1175-1181.                      | 1.7 | 101       |
| 47 | Predicting Drug Disposition via Application of a Biopharmaceutics Drug Disposition Classification System. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 162-167.   | 1.2 | 98        |
| 48 | Premarketing observational studies of population pharmacokinetics of new drugs. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 481-487.  | 2.3 | 96        |
| 49 | CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 143-155.   | 1.3 | 96        |
| 50 | Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. <i>British Journal of Pharmacology</i> , 2000, 129, 1235-1243.   | 2.7 | 92        |
| 51 | HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1311-1316.  | 1.7 | 91        |
| 52 | The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation in Patients and to Designing Extended Release Dosage Forms. <i>Pharmaceutical Research</i> , 2008, 25, 2869-2877.  | 1.7 | 85        |
| 53 | Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.   | 2.9 | 82        |
| 54 | Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. <i>Pharmaceutical Research</i> , 2001, 18, 1102-1109.  | 1.7 | 80        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1336-1344. | 1.7 | 78        |
| 56 | BDDCS Class Prediction for New Molecular Entities. <i>Molecular Pharmaceutics</i> , 2012, 9, 570-580.  | 2.3 | 78        |
| 57 | The BCS, BDDCS, and Regulatory Guidances. <i>Pharmaceutical Research</i> , 2011, 28, 1774-1778.  | 1.7 | 77        |
| 58 | In Vitro and in Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms. <i>Pharmaceutical Research</i> , 1990, 07, 975-982.  | 1.7 | 72        |
| 59 | Disposition and irreversible plasma protein binding of tolmetin in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 107-114.  | 2.3 | 71        |
| 60 | DISPOSITION OF TACROLIMUS IN ISOLATED PERFUSED RAT LIVER: INFLUENCE OF TROLEANDOMYCIN, CYCLOSPORINE, AND GG918. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1292-1295.  | 1.7 | 69        |
| 61 | Effect of route of administration and distribution on drug action. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 559-585.   | 0.6 | 68        |
| 62 | Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat. <i>Pharmacology</i> , 1998, 56, 308-313.   | 0.9 | 68        |
| 63 | Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 121-127.   | 2.3 | 67        |
| 64 | Pharmacokinetics and metabolism of bepridil. <i>American Journal of Cardiology</i> , 1985, 55, C8-C13.   | 0.7 | 67        |
| 65 | High-fat meals increase the clearance of cyclosporine. <i>Pharmaceutical Research</i> , 1990, 07, 46-48.   | 1.7 | 66        |
| 66 | Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , 2016, 3, e521-e528.          | 2.1 | 66        |
| 67 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 95-109.   | 6.6 | 65        |
| 68 | Kinetics of oral ethambutol in the normal subject. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 615-621.  | 2.3 | 64        |
| 69 | Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2751-2757.                  | 1.6 | 64        |
| 70 | An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 123, 502-514.                                    | 1.9 | 63        |
| 71 | BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. <i>AAPS Journal</i> , 2016, 18, 251-260.                           | 2.2 | 60        |
| 72 | Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4413-4419.                                      | 1.6 | 58        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1988, 16, 475-492.    | 0.6  | 55        |
| 74 | Distinguishing between the Permeability Relationships with Absorption and Metabolism To Improve BCS and BDDCS Predictions in Early Drug Discovery. <i>Molecular Pharmaceutics</i> , 2014, 11, 1335-1344.                      | 2.3  | 55        |
| 75 | Hypersensitivity to nonsteroidal anti-inflammatory drugs. <i>Nature Medicine</i> , 1995, 1, 2-4.  | 15.2 | 54        |
| 76 | Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. <i>Toxicological Sciences</i> , 2018, 162, 499-508.   | 1.4  | 53        |
| 77 | The Critical Role of Passive Permeability in Designing Successful Drugs. <i>ChemMedChem</i> , 2020, 15, 1862-1874.  | 1.6  | 53        |
| 78 | Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.          | 0.5  | 52        |
| 79 | The renal elimination of procainamide. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 55-62.   | 2.3  | 50        |
| 80 | Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 828-832.   | 2.3  | 48        |
| 81 | Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. <i>AAPS Journal</i> , 2018, 20, 46.   | 2.2  | 46        |
| 82 | The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 358-363. | 1.7  | 44        |
| 83 | Volume Terms in Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 1969, 58, 639-641.  | 1.6  | 43        |
| 84 | Pharmacokinetics of cefamandole using a HPLC assay. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 153-164.   | 0.6  | 42        |
| 85 | Hepatic Clearance Predictions from In Vitro-In Vivo Extrapolation and the Biopharmaceutics Drug Disposition Classification System. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1731-1735.                              | 1.7  | 42        |
| 86 | Evaluation of DILI Predictive Hypotheses in Early Drug Development. <i>Chemical Research in Toxicology</i> , 2017, 30, 1017-1029.   | 1.7  | 42        |
| 87 | Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.   | 3.2  | 42        |
| 88 | In Vitro-In Vivo Extrapolation and Hepatic Clearance-Dependent Underprediction. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2500-2504.   | 1.6  | 42        |
| 89 | Probenecid-induced changes in the clearance of carprofen enantiomers: A preliminary study. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 500-505.   | 2.3  | 40        |
| 90 | Red wine decreases cyclosporine bioavailability. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 468-474.   | 2.3  | 39        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Effects of Uremic Toxins on Transport and Metabolism of Different Biopharmaceutics Drug Disposition Classification System Xenobiotics. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3831-3842.   | 1.6 | 39        |
| 92  | Attenuation of furosemide's diuretic effect by indomethacin: Pharmacokinetic evaluation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 265-274.   | 0.6 | 38        |
| 93  | Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. , 1998, 15, 1520-1524.   |     | 38        |
| 94  | Renal excretion of pseudoephedrine. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 690-694.   | 2.3 | 37        |
| 95  | Elucidating the Effect of Final-Day Dosing of Rifampin in Induction Studies on Hepatic Drug Disposition and Metabolism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 319, 864-870.   | 1.3 | 37        |
| 96  | Transdermal bioavailability and first-pass skin metabolism: A preliminary evaluation with nitroglycerin. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1987, 15, 423-437.  | 0.6 | 36        |
| 97  | Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 673-680.  | 2.3 | 36        |
| 98  | There Are No Useful CYP3A Probes that Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and No Expectation that One Will Be Found. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005, 5, 79-83. | 3.4 | 36        |
| 99  | Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro. <i>Pharmaceutical Research</i> , 1990, 07, 21-27.   | 1.7 | 35        |
| 100 | The FDA Should Eliminate the Ambiguities in the Current BCS Biowaiver Guidance and Make Public the Drugs for Which BCS Biowaivers Have Been Granted. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 405-407.  | 2.3 | 35        |
| 101 | Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 273-277.   | 2.3 | 33        |
| 102 | Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. <i>Pharmaceutical Research</i> , 1989, 06, 486-491.  | 1.7 | 33        |
| 103 | Hydrochlorothiazide Pharmacokinetics and Pharmacologic Effect: The Influence of Indomethacin. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 32-41.   | 1.0 | 32        |
| 104 | The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 521-525.   | 2.3 | 32        |
| 105 | Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. <i>Pharmacology</i> , 2020, 105, 145-163.   | 0.9 | 32        |
| 106 | Predicting when Biliary Excretion of Parent Drug is a Major Route of Elimination in Humans. <i>AAPS Journal</i> , 2014, 16, 1085-1096.   | 2.2 | 31        |
| 107 | Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCS. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3229-3235.   | 1.6 | 31        |
| 108 | Ascorbic acid metabolites are involved in intraocular pressure control in the general population. <i>Redox Biology</i> , 2019, 20, 349-353.  | 3.9 | 31        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Use of General Partial Fraction Theorem for Obtaining Inverse Laplace Transforms in Pharmacokinetic Analysis. <i>Journal of Pharmaceutical Sciences</i> , 1971, 60, 1593-1594.   | 1.6 | 30        |
| 110 | Acute Massive Chloral Hydrate Intoxication Treated with Hemodialysis: A Clinical Pharmacokinetic Analysis. <i>Journal of Clinical Pharmacology</i> , 1978, 18, 136-142.  | 1.0 | 30        |
| 111 | A standard approach to compiling clinical pharmacokinetic data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 59-127.   | 0.6 | 30        |
| 112 | Glutathione S-transferase-mediated metabolism of glyceryl trinitrate in subcellular fractions of bovine coronary arteries. <i>Pharmaceutical Research</i> , 1992, 09, 1460-1464.   | 1.7 | 29        |
| 113 | Is Ciprofloxacin a Substrate of P-glycoprotein?. <i>Archives of Drug Information</i> , 2011, 4, 1-9.   | 1.6 | 29        |
| 114 | Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 442-451.     | 1.1 | 29        |
| 115 | Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3546-3559.  | 2.9 | 29        |
| 116 | Furosemide kinetics and dynamics after kidney transplant. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 105-113.   | 2.3 | 28        |
| 117 | Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 425-429.   | 2.3 | 28        |
| 118 | A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. <i>Pharmaceutical Research</i> , 2001, 18, 39-44.   | 1.7 | 28        |
| 119 | An integrated approach to the pharmacokinetic analysis of drug absorption. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1974, 2, 525-544.   | 0.6 | 27        |
| 120 | Clearance (nÅ©e Rowland) concepts: a downdate and an update. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010, 37, 529-539.  | 0.8 | 27        |
| 121 | Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 540-547.   | 2.3 | 27        |
| 122 | The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria. <i>AAPS Journal</i> , 2014, 16, 1358-1365.  | 2.2 | 27        |
| 123 | Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 592-598.  | 2.3 | 26        |
| 124 | Pharmacokinetics of nicotinic acid & salicylic acid interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 642-647.  | 2.3 | 25        |
| 125 | Are There Any Experimental Perfusion Data that Preferentially Support the Dispersion and Parallel-Tube Models over the Well-Stirred Model of Organ Elimination?. <i>Drug Metabolism and Disposition</i> , 2020, 48, 537-543. | 1.7 | 25        |
| 126 | Drug metabolism and laboratory anesthetic protocols in the rat: examination of antipyrine pharmacokinetics. <i>Pharmaceutical Research</i> , 1991, 08, 544-546.  | 1.7 | 24        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum. <i>Pharmaceutical Research</i> , 1999, 16, 221-224.                       | 1.7 | 24        |
| 128 | Pharmacokinetics of Orally and Intravenously Administered Cyclosporine in Pre-renal Kidney Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 60-67.                             | 1.0 | 22        |
| 129 | Predicting the Extent of Metabolism Using <i>in Vitro</i> Permeability Rate Measurements and <i>in Silico</i> Permeability Rate Predictions. <i>Molecular Pharmaceutics</i> , 2015, 12, 1456-1466.     | 2.3 | 22        |
| 130 | How Transporters Have Changed Basic Pharmacokinetic Understanding. <i>AAPS Journal</i> , 2019, 21, 103.  | 2.2 | 22        |
| 131 | State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. <i>AAPS Journal</i> , 2022, 24, 37.              | 2.2 | 22        |
| 132 | Nitroglycerin absorption from transdermal systems: formulation effects and metabolite concentrations. <i>Pharmaceutical Research</i> , 1991, 08, 744-749.  | 1.7 | 21        |
| 133 | pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. <i>Pharmaceutical Research</i> , 2015, 32, 2516-26.                           | 1.7 | 21        |
| 134 | Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain. <i>Clinical Pharmacokinetics</i> , 2016, 55, 143-167.         | 1.6 | 21        |
| 135 | Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 155-163.                | 0.8 | 21        |
| 136 | Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways. <i>AAPS Journal</i> , 2020, 22, 120. | 2.2 | 21        |
| 137 | Absorption kinetics of cyclosporine in healthy volunteers. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 591-596.   | 1.1 | 19        |
| 138 | Evaluation of the relevance of DILI predictive hypotheses in early drug development: review of <i>in vitro</i> methodologies vs. BDDCS classification. <i>Toxicology Research</i> , 2018, 7, 358-370.  | 0.9 | 19        |
| 139 | The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. <i>Pharmaceutical Research</i> , 2018, 35, 242.  | 1.7 | 19        |
| 140 | There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. <i>AAPS Journal</i> , 2021, 23, 67.    | 2.2 | 19        |
| 141 | A Holy Grail of Clinical Pharmacology: Prediction of Drug Pharmacokinetics and Pharmacodynamics in the Individual Patient. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 133-134.          | 2.3 | 18        |
| 142 | Sotalol Permeability in Cultured-Cell, Rat Intestine, and PAMPA System. <i>Pharmaceutical Research</i> , 2012, 29, 1768-1774.  | 1.7 | 18        |
| 143 | Cefamandole kinetics in uremic patients undergoing hemodialysis. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 592-599.  | 2.3 | 17        |
| 144 | Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 590-596.                                 | 2.3 | 17        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Chiral Bioequivalence. <i>Clinical Pharmacokinetics</i> , 2000, 39, 459-469.   | 1.6 | 16        |
| 146 | Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria. <i>Molecular Pharmaceutics</i> , 2013, 10, 4032-4037.   | 2.3 | 16        |
| 147 | Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties. <i>Pharmaceutical Research</i> , 2019, 36, 113.   | 1.7 | 16        |
| 148 | Can <i>In Vitro</i> "In Vivo" Extrapolation Be Successful? Recognizing the Incorrect Clearance Assumptions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1022-1035.  | 2.3 | 16        |
| 149 | Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). <i>Chinese Journal of Natural Medicines</i> , 2016, 14, 888-897.  | 0.7 | 15        |
| 150 | Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition. <i>Pharmaceutical Research</i> , 2020, 37, 208.  | 1.7 | 15        |
| 151 | Peptides and proteins as drugs. <i>Pharmaceutical Research</i> , 1985, 02, 151-156.  | 1.7 | 14        |
| 152 | Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. <i>AAPS Journal</i> , 2016, 18, 757-766.     | 2.2 | 14        |
| 153 | In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. <i>Chirality</i> , 1993, 5, 120-125.   | 1.3 | 13        |
| 154 | HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. <i>Pharmaceutical Research</i> , 1994, 11, 844-847.  | 1.7 | 13        |
| 155 | Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 369-383.                          | 0.8 | 13        |
| 156 | Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies has not been Justified and on Balance is Not Useful. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 44-51. | 1.2 | 13        |
| 157 | TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2018, 8, 571-586.                                   | 1.4 | 13        |
| 158 | An integrated approach to pharmacokinetic analysis for linear mammillary systems in which input and exit may occur in/from any compartment. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989, 17, 673-686.                           | 0.6 | 12        |
| 159 | Insights into solute carriers: physiological functions and implications in disease and pharmacokinetics. <i>MedChemComm</i> , 2016, 7, 1462-1478.  | 3.5 | 12        |
| 160 | Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2895-2898.  | 1.6 | 12        |
| 161 | Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 431-441.   | 0.7 | 11        |
| 162 | Evaluating Within-Subject Variability for Narrow Therapeutic Index Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 411-416.  | 2.3 | 11        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 205-222.  | 1.6 | 11        |
| 164 | Effects of Indomethacin and Carprofen on Renal Homeostasis in Rheumatoid Arthritis Patients and in Healthy Individuals. <i>Journal of Clinical Pharmacology</i> , 1981, 21, 493-500.   | 1.0 | 10        |
| 165 | Ion-Paired Liquid Chromatographic Method for the Analysis of Pyridostigmine in Plasma. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1987, 10, 2231-2246.   | 0.9 | 10        |
| 166 | In Vitro-In Vivo Inaccuracy: The CYP3A4 Anomaly. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1368-1371.   | 1.7 | 10        |
| 167 | The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions. <i>AAPS Journal</i> , 2020, 22, 111.   | 2.2 | 10        |
| 168 | Use of the unanesthetized rhesus monkey as a model for studying the gastrointestinal absorption of drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1974, 2, 417-431.  | 0.6 | 9         |
| 169 | HPLC Measurement of Cyclosporine in Blood Plasma and Urine and Simultaneous Measurement of its Four Metabolites in Blood. , 1989, 12, 1451-1462.   |     | 9         |
| 170 | Addendum 1. Use of isotopes in bioavailability testing. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1973, 1, 83-87.  | 0.6 | 8         |
| 171 | Saturable kinetics of intravenous chlorothiazide in the rhesus monkey. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1981, 9, 461-476.   | 0.6 | 8         |
| 172 | Percutaneous penetration kinetics of nitroglycerin and its dinitrate metabolites across hairless mouse skin in vitro. <i>Pharmaceutical Research</i> , 1991, 08, 1231-1237.  | 1.7 | 8         |
| 173 | Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. <i>Pharmaceutical Research</i> , 2017, 34, 619-628.   | 1.7 | 8         |
| 174 | A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 306-315.                             | 2.3 | 8         |
| 175 | Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 979-989.   | 1.0 | 7         |
| 176 | Can BDDCS illuminate targets in drug design?. <i>Drug Discovery Today</i> , 2019, 24, 2299-2306.   | 3.2 | 7         |
| 177 | Characterization of Fasiglifam-Related Liver Toxicity in Dogs. <i>Drug Metabolism and Disposition</i> , 2019, 47, 525-534.   | 1.7 | 7         |
| 178 | Protein Binding and Hepatic Clearance: Re-Examining the Discrimination between Models of Hepatic Clearance with Diazepam in the Isolated Perfused Rat Liver Preparation. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1397-1402. | 1.7 | 7         |
| 179 | High Pressure Liquid Chromatographic Determination of Mecillinam in Human Plasma and Urine. <i>Analytical Letters</i> , 1981, 14, 1433-1447.   | 1.0 | 6         |
| 180 | Membrane Populations of Bovine Choroid Plexus: Separation by Density Gradient Centrifugation in Modified Colloidal Silica. <i>Journal of Neurochemistry</i> , 1982, 37, 768-774.   | 2.1 | 6         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Pharmacokinetics of nitroglycerin and its four metabolites during nitroglycerin transdermal administration. <i>Biopharmaceutics and Drug Disposition</i> , 1994, 15, 179-183.  | 1.1 | 6         |
| 182 | Benet L Z and Galeazzi R L: Noncompartmental Determination of the Steady-State Volume of Distribution, <i>J Pharm Sci</i> 68, 1071-1074, 1979-the Backstory. <i>AAPS Journal</i> , 2012, 14, 164-167.                                | 2.2 | 6         |
| 183 | Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (K <sub>puu</sub> ) on Prediction of Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2020, 37, 73.   | 1.7 | 6         |
| 184 | Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System. <i>Pharmacotherapy</i> , 2020, 40, 274-290.   | 1.2 | 6         |
| 185 | Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 215-222.   | 1.1 | 5         |
| 186 | Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study. <i>Pharmaceutical Research</i> , 1993, 10, 889-894.                                      | 1.7 | 5         |
| 187 | Immunopharmacodynamic Studies of Cyclosporine in Patients Awaiting Renal Transplantation. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 967-973.   | 1.0 | 5         |
| 188 | The Enhancement of Subcutaneous First-Pass Metabolism Causes Nonlinear Pharmacokinetics of TAK-448 after a Single Subcutaneous Administration to Rats. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1004-1012.                 | 1.7 | 5         |
| 189 | Batch-to-Batch and Within-Subject Variability: What Do We Know and How Do These Variabilities Affect Clinical Pharmacology and Bioequivalence?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 326-328.                  | 2.3 | 5         |
| 190 | Investigating Intestinal Transporter Involvement in Rivaroxaban Disposition through Examination of Changes in Absorption. <i>Pharmaceutical Research</i> , 2021, 38, 795-801.  | 1.7 | 5         |
| 191 | Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans. <i>Pharmaceutical Research</i> , 2021, 38, 1139-1156.                        | 1.7 | 5         |
| 192 | Time course of cyclosporine and its metabolites in blood, liver and spleen of naive lewis rats: Comparison with preliminary data obtained in transplanted animals. <i>Biopharmaceutics and Drug Disposition</i> , 1995, 16, 303-312. | 1.1 | 4         |
| 193 | Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. <i>Scientific Reports</i> , 2018, 8, 92.  | 1.6 | 4         |
| 194 | Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. <i>Biopharmaceutics and Drug Disposition</i> , 1991, 12, 467-477.  | 1.1 | 3         |
| 195 | Determination of aliphatic thiols by fluorometric high-performance liquid chromatography after precolumn derivatization with 2-(4-N-maleimidophenyl)-6-methylbenzothiazole. <i>Pharmaceutical Research</i> , 1995, 12, 155-160.      | 1.7 | 3         |
| 196 | Understanding the Potential Interethnic Difference in Rosuvastatin Pharmacokinetics. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2231-2233.   | 1.6 | 3         |
| 197 | Food, Acid Supplementation and Drug Absorption – a Complicated Gastric Mix: a Randomized Control Trial. <i>Pharmaceutical Research</i> , 2019, 36, 155.  | 1.7 | 3         |
| 198 | Analyzing Potential Intestinal Transporter Drug-Drug Interactions: Reevaluating Ticagrelor Interaction Studies. <i>Pharmaceutical Research</i> , 2021, 38, 1639-1644.  | 1.7 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 199 | Does Addition of Protein to Hepatocyte or Microsomal In Vitro Incubations Provide a Useful Improvement in In Vitro-In Vivo Extrapolation Predictability?. Drug Metabolism and Disposition, 2022, 50, 401-412.   | 1.7 | 3         |
| 200 | Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat. Pharmaceutical Research, 1991, 08, 877-882.  | 1.7 | 2         |
| 201 | Review and Critique of the Institute of Medicine Report "The Future of Drug Safety". Clinical Pharmacology and Therapeutics, 2007, 81, 158-161.   | 2.3 | 2         |
| 202 | Effect of P-Glycoprotein on the Rat Intestinal Permeability and Metabolism of the BDDCS Class 1 Drug Verapamil. Molecular Pharmaceutics, 2013, 10, 4038-4045.   | 2.3 | 2         |
| 203 | A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 377-383.   | 0.2 | 2         |
| 204 | Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 110, 480-485.   | 2.3 | 2         |
| 205 | Transporter-Based Drug "Drug Interactions and Their Effect on Distribution Volumes. , 2010, , 437-471.  |     | 1         |
| 206 | A Step Closer to Personalized Chemotherapy: Consideration of the Influence of Genetic Variation in Hepatic Uptake Transporters on the Metabolism of CYP3A Substrates. Clinical Pharmacology and Therapeutics, 2012, 92, 551-552.  | 2.3 | 1         |
| 207 | Response of authors to Ganju and Dias's comments on "Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful" by D. A. Parasrampur and L. Z. B. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 367-367. | 1.2 | 0         |
| 208 | Using Individualized Patient Data for Prediction of Population Dosing Recommendations Versus Predictions of Individualized Patient Dosing. Journal of Clinical Pharmacology, 2021, 61, 734-735.   | 1.0 | 0         |
| 209 | Morality Play. Science, 1996, 273, 1782-1782.   | 6.0 | 0         |